Weight Loss Injections and Cancer Risk: What the Evidence Actually Shows

What the clinical trials found, and what they did not

When people ask about weight loss injections and cancer risk, they are usually responding to something they read online. That scepticism is healthy. The large phase-3 trials underpinning the licensed medicines in the UK (including SURMOUNT-1 for tirzepatide and STEP 1 for semaglutide) were not primarily designed to measure cancer outcomes over decades, and no medicine trial of two to three years duration can definitively answer a question that cancer biology sometimes takes many years to answer.

What those trials did show is that no statistically significant increase in cancer rates was observed in the treatment groups compared with placebo. The NHS patient information for tirzepatide does not list cancer as a known side effect, and the MHRA's regulatory review of both semaglutide and tirzepatide reached the same conclusion before granting licences for weight management. That is not the same as saying risk has been proven zero for all time, long-term pharmacovigilance continues for all Black Triangle medicines.

The one area where a specific signal does exist in preclinical (animal) data is the thyroid. Rodent studies showed thyroid C-cell tumours at high doses of GLP-1 medicines; however, C-cells in humans do not respond in the same way as in rodents, and no human trial data has established this link. For more detail on what is and is not known about this specific question, our page on weight loss injections and thyroid cancer covers the evidence carefully.

The contraindication that matters most: MTC and MEN2

There is one clear, well-established rule in the prescribing guidance for both Mounjaro and Wegovy: neither medicine is suitable for people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2). This is not a theoretical concern extrapolated from animal data alone, it is a defined contraindication in the Summary of Product Characteristics for both medicines, and it is something every prescriber at a regulated UK service is required to screen for before issuing a prescription.

At nume, the consultation is reviewed personally by a GPhC-registered Independent Prescriber. That means a real clinician reads your answers (not software running an eligibility filter) and your medical history is taken seriously. If there is any family history of thyroid cancer or MEN2, a prescriber will discuss what that means for your suitability. You can read more about how the overall risk assessment works on our broader guide to weight loss injection risks.

People with a history of other cancers, or who are currently receiving cancer treatment, should also raise this with their prescriber and their oncology team. The consultation is the right place for that conversation, not a checklist.

Obesity, cancer, and the bigger picture

Any honest assessment of cancer risk alongside weight-loss injections has to acknowledge the direction of travel in the other direction. Obesity is a recognised risk factor for at least 13 cancers, including breast, bowel, kidney, and oesophageal cancer, according to NHS guidance. Carrying excess weight raises circulating levels of oestrogen, insulin and inflammatory markers, all of which are implicated in cancer biology.

This does not mean GLP-1 medicines prevent cancer. That claim would require long-term outcome data that does not yet exist. If you are weighing up whether treatment is right for you, our guide to what a weight loss injection involves explains how these medicines work and what the licensed options currently are. What it does mean is that the question of cancer risk cannot sensibly be separated from the risk that sustained obesity itself carries. The NHS overview of obesity sets this out clearly, and the MHRA's own public guidance on GLP-1 medicines acknowledges that the reduction in weight-related health risks is central to why these medicines are licensed.

Researchers are following large cohorts of patients on GLP-1 medicines precisely because this is a clinically important question. The evidence will mature. For now, the licensed position (grounded in trial data and regulatory review) is that these medicines do not increase cancer risk in the populations studied, and carry defined contraindications that any legitimate prescriber will act on. A question our prescribers hear regularly is whether a past cancer diagnosis rules treatment out entirely; if that question applies to you, our page on weight loss injections and cancer looks at what the current evidence and prescribing guidance say, and is a good place to start before your consultation.

When to get medical help, and how to report concerns

Starting a new medicine means knowing which symptoms need prompt attention. For weight-loss injections specifically, the symptoms that should prompt you to contact a clinician or go to A&E include: severe or persistent stomach pain that extends toward the back (a possible sign of pancreatitis, flagged in a January 2026 MHRA Drug Safety Update for GLP-1 medicines), any lump or swelling in your neck, hoarseness that develops or worsens without explanation, or difficulty swallowing. These are not common, but they are the signals that matter.

More general warning signs (unexplained weight loss beyond what treatment would account for, blood in urine or stool, persistent fatigue, or any new lump anywhere) should be reported to your GP regardless of whether you are on a weight-loss injection. They are not attributable to the medicine and should be investigated on their own merits. For those who want to understand the specific research in this area more deeply, our pages on whether weight loss injections can cause cancer and on weight loss injections and breast cancer look at what the studies currently show for those particular questions.

If you experience a symptom you believe is related to your treatment, you can report it directly via the MHRA's Yellow Card scheme. This reporting system is how the UK maintains post-market surveillance on medicines including the newer GLP-1 treatments; your report contributes to the evidence base for everyone. If you have questions about a specific symptom or your suitability for treatment, you can also contact our team. Our prescribers discuss suitability and side effects as part of every consultation (including any concerns about cancer history) so starting that conversation costs nothing. Speak to our prescribers if you would like a personalised assessment.